Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2019 · 10-Q
Revenue$7.01M$7.01M+37.4% vs Q2 2018 Net Income$406.62K$406.62K+45.0% vs Q2 2018 EPS Diluted$0.03$0.03+50.0% vs Q2 2018 Gross Profit$4,319,148+50.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$81,769N/M Free Cash Flowderived-$115,660— Margins · derivedGross margin61.6%+5.5 pt vs Q2 2018
Operating margin6.9%+1.5 pt vs Q2 2018
Net margin5.8%+0.3 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end